Bavarian stock price drops despite guidance upgrade and EU monkeypox vaccine order
Looking for an explanation for why Bavarian’s newest vaccine contract hasn’t been met with market enthusiasm, one Sydbank analyst points to a generally rainy trading day.
by marketwire, translated by daniel pedersen
The European Union had already indicated interest in a shared purchase of vaccine doses for monkeypox, so Tuesday’s news that the EU has signed a contract shouldn’t have come as a big surprise, according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EU orders 110,000 monkeypox vaccine doses for member states
For subscribers
Bavarian Nordic says more upgrades could be on the way
For subscribers
